// App-Quantinova.ai

Su1922 : HISTOLOGICAL REMISSION IS PREDICTIVE OF IMPROVED CLINICAL OUTCOMES IN PATIENTS WITH ULCERATIVE COLITIS: RESULTS FROM THE TOUCHSTONE OLE

Researchers

Presenter

  • Brian G. Feagan

Principal Investigators

  • Geert R. D'Haens

  • Richard Aranda

  • Allan Olson

  • Barrett Levesque

  • Rish Pai

  • Stephen B. Hanauer

  • Douglas C. Wolf

  • Severine Vermeire

  • Subrata Ghosh

  • Caiyan Li

  • Darryl Penenberg

Medical Centers

  • University of Calgary, Calgary, AB, Canada

  • Feinberg School of Medicine, Chicago, Illinois, United States

  • University of Leuven, KUL, Leuven, Belgium

  • Department of Laboratory Medicine and Pathology, Mayo Clinic, Scottsdale, Arizona, United States

  • Academic Medical Center, Amsterdam, Netherlands

  • University of California, San Francisco, San Francisco, California, United States

  • Atlanta Gastroenterology Associates, Atlanta, Georgia, United States

  • Robarts Reserach Institute, London, ON, Canada

Locations

  • United States

  • Canada

  • Belgium

  • Netherlands

Companies

  • Celgene Corporation

Study Components

Therapeutic Area

  • Blood/haematological Diseases

Disease

  • N/A

Biomarkers

  • Alanine transaminase

  • Aspartate aminotransferase

Drug/Treatment

  • Ozanimod

Outcome

  • Unknown

Study Design

  • open label

  • randomized

  • double blind/blinded

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved